PINK1 and neoplasm: Because a single inhibitor or antineoplastic agent against PINK1 has great limitations, future studies are warranted and necessary to determine whether reducing PINK1 expression, especially in combination with chemical anti-tumor agents (63–66), could constitute a viable approach to combat mutant Ras-induced and other types of cancers.